78 related articles for article (PubMed ID: 9125151)
1. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells.
Ishioka C; Shimodaira H; Englert C; Shimada A; Osada M; Jia LQ; Suzuki T; Gamo M; Kanamaru R
Biochem Biophys Res Commun; 1997 Mar; 232(1):54-60. PubMed ID: 9125151
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo.
Ishioka C; Englert C; Winge P; Yan YX; Engelstein M; Friend SH
Oncogene; 1995 Apr; 10(8):1485-92. PubMed ID: 7731702
[TBL] [Abstract][Full Text] [Related]
3. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T; Kato S; Otsuka K; Watanabe G; Kumabe T; Tominaga T; Yoshimoto T; Ishioka C
Oncogene; 2005 Oct; 24(46):6976-81. PubMed ID: 16007150
[TBL] [Abstract][Full Text] [Related]
4. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
5. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
6. p53 mutants without a functional tetramerisation domain are not oncogenic.
Chène P; Bechter E
J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
[TBL] [Abstract][Full Text] [Related]
7. Suppression of high-density magnetic field (400 mT at 50 Hz)-induced mutations by wild-type p53 expression in human osteosarcoma cells.
Miyakoshi J; Mori Y; Yamagishi N; Yagi K; Takebe H
Biochem Biophys Res Commun; 1998 Feb; 243(2):579-84. PubMed ID: 9480851
[TBL] [Abstract][Full Text] [Related]
8. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
[TBL] [Abstract][Full Text] [Related]
10. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
11. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
12. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
[TBL] [Abstract][Full Text] [Related]
13. The role of tetramerization in p53 function.
Chène P
Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
[TBL] [Abstract][Full Text] [Related]
14. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
15. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
16. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
18. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
20. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]